Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, November 11, 2019

Seaweed-Based Drug Approved for Alzheimer's in China

What is your doctor and stroke hospital doing to ensure this gets tested for our use? NOTHING? Then have them fired. Or do they prefer you travel to China for medical interventions?  


Your chances of getting dementia.


1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.


2. Then this study came out and seems to have a range from 17-66%. December 2013.


3. A 20% chance in this research.   July 2013.


4. Dementia Risk Doubled in Patients Following Stroke September 2018 


5. Parkinson’s Disease May Have Link to Stroke March 2017

Seaweed-Based Drug Approved for Alzheimer's in China

Oligomannate appears to affect gut microbiota, peripheral inflammation

A school of fish swim through seaweed
A seaweed-derived oligomannate preparation (GV-971) received approval from China's National Medical Products Administration (NMPA) to treat mild to moderate Alzheimer's disease, Shanghai Green Valley Pharmaceuticals announced.
A phase III clinical trial of 818 patients with mild-to-moderate Alzheimer's disease showed that oligomannate improved cognition by week 4, showing a mean difference in ADAS-Cog 12 scores of 2.54 (P< 0.0001) between treatment and placebo arms with sustained efficacy until the end of 9 months of treatment, Green Valley said in a press release. The drug was well tolerated and adverse effects in each arm were comparable, the company added.
Full outcomes of the trial have not yet been published, but preclinical data reported in Cell Research showed that, in mice, sodium oligomannate changed gut microbiota, modulated peripheral and central inflammation, and was tied to changes in behavior and Alzheimer's-related pathology. In a commentary accompanying the preclinical study, David Holtzman, MD, of Washington University in St. Louis, and co-authors noted that "GV-971 decreases Aβ-related pathologies by reconditioning the gut microbiota, providing further evidence that gut-targeted interventions may serve as novel strategies to tackle Alzheimer's disease."
The mechanistic relationship between the microbiome and Alzheimer's remains unclear. Increasingly, researchers are looking at ways other organs may affect brain changes: altered liver enzymes have been linked to Alzheimer's disease and people who have had their appendix removed were shown to have a nearly 20% lower risk of Parkinson's disease.
The NMPA's decision marks the first novel drug approved globally for Alzheimer's disease since 2003, Green Valley said. The approval is conditional and will have monitoring for safety. The company plans a multinational phase III trial next year in the U.S, Europe, and Asia to support regulatory filings in other countries.

No comments:

Post a Comment